Bionano Genomics, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Bionano Genomics, Inc. (Nasdaq: BNGO) provides genome analysis solutions, including optical genome mapping (OGM) systems, platform-agnostic software and nucleic acid extraction technologies, enabling researchers and clinicians to detect structural variations across basic, translational and clinical research in oncology, constitutional genetic disorders, reproductive health and cell line quality control. The company offers the Saphyr system for ultra-sensitive OGM detection of all classes of structural variants from ultra-high molecular weight DNA; the Stratys high-throughput OGM system; VIA software for integrated analysis, visualization and reporting of OGM, next-generation sequencing and microarray data including copy number variants and single-nucleotide variants; Solve software with AI-powered workflows for hematological malignancies and constitutional disorders, featuring an 18% expanded structural variants database; and the Ionic system utilizing isotachophoresis for high-quality DNA and RNA extraction from cells, tissue and FFPE samples. Founded in 2003 and headquartered in San Diego, California, Bionano Genomics operates globally in the Americas, Europe, Middle East, Africa and Asia-Pacific, serving academic institutions, pharmaceutical companies, clinical laboratories and cytogenetics professionals through direct sales and distribution partners. Recent developments include the full commercial release of the Stratys system in 2024; major upgrades to VIA 7.2 and Solve 3.8.3 software in 2025 with enhanced AI capabilities, doubled cancer sample throughput on Stratys Compute servers and interoperability improvements, initially available to early access users with broad release in Q4 2025; a $10 million public offering of common stock completed in September 2025; CMS preliminary payment determination for Category I CPT codes covering OGM in constitutional genetic disorders; and presentation of nine OGM studies at the 2025 American Society of Human Genetics meeting highlighting global adoption momentum.
Company News
Bionano Laboratories Announces Expansion of Diagnostic Testing Based on Optical Genome Mapping for Hematologic Malignancies
Bionano Announces Three New Peer-Reviewed Studies Demonstrate Clinical Value of Bionano's Optical Genome Mapping Across Myelodysplastic Syndromes and Acute Myeloid Leukemia
Bionano Laboratories Announces Proposed Local Coverage Determination (LCD) from MolDX for Genome-Wide Detection of Structural Variants in Hematologic Neoplasms
Bionano Laboratories Announces New York State Department of Health Approval of Lab Developed Tests Based on Optical Genome Mapping
Bionano to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Bionano Genomics, Inc. (BNGO) Q2 2026 Earnings Call Transcript
Bionano to Report Second Quarter 2026 Financial Results and Host a Conference Call Webcast on August 10, 2026
Bionano Announces Hiring of Chief Scientific Officer
Bionano Announces 67% Year-Over-Year Growth in Studies Featuring Optical Genome Mapping at ESHG 2026, Reflecting Expanding Global Adoption
Bionano Announces Multiple Publications in 2026 Describing Unique Utility of OGM in Studies of Reproductive Health and Prenatal Genetic Disorders
Bionano Genomics (BNGO) Upgraded to Buy: What Does It Mean for the Stock?
Why Fast-paced Mover Bionano Genomics (BNGO) Is a Great Choice for Value Investors
Bionano Announces Full Retirement of Outstanding Senior Secured Convertible Debentures
Bionano Announces Largest OGM Study of T-Cell Acute Lymphoblastic Leukemia
Bionano Genomics, Inc. (BNGO) Q1 2026 Earnings Call Transcript
Bionano Genomics, Inc. (BNGO) Reports Q1 Loss, Tops Revenue Estimates
Bionano Reports First Quarter 2026 Results and Provides a Business Update
Bionano Announces Leadership Transition
Bionano Announces a 56% Increase in Publications Describing the Utility of OGM in Rare Diseases in Q1 2026 vs Q1 2025
Bionano to Report First Quarter 2026 Financial Results and Host a Conference Call Webcast on May 13, 2026